

Cost benefit of investing in health systems

Jonathan Rushton,

Professor of Animal Health Economics

jrushton@rvc.ac.uk

with

Derrick Jones and Liz Redmond

Acknowledgements

- ▾ VEEPH Group at RVC: Barbara Haesler, Liz Jackson, Pablo Alarcon, Paula Dominguez-Salas, Betty Bisdorf, Will Gilbert, Sara Babo Martins, Mieghan Bruce, Richard Kock, Dirk Pfeiffer
- ▾ LCIRAH – Andrew Dorward, Lili Jia, Colin Poulton
- ▾ Ruth Rushton, Jane Dixon, Colin Butler, Robyn Alders, Ian Patrick, Peter Daniels, Mark Rweyemamu
- ▾ Thank you to the organisers for the invitation to present at the meeting with a special mention for Bernard Vallat
- ▾ I want recognise the support of Norbrook Pharmaceuticals and LCIRAH in the work I carry out

Introduction

- Historically the presence of disease has generated societal responses such as improved policies for surveillance, control and prevention.
- The institutionalisation of these responses in many societies has led to a separation between the core investment in health systems and investment in programmes to address specific diseases.

Introduction

- Over the last decades it has been increasingly important to present the economic assessment of specific disease programmes, and more recently to justify the general costs that underpin the overall health system.
- The OIE has supported this work with the development of the Performance of Veterinary Services (PVS) tool to identify strengths and weakness in core health systems, and the diseases whose control is essential for economic development.

What is the problem?

- › Despite the successes of the approach of investing

The problem is the **weakness in core activities** undermines specific disease programmes
Overall there appears to be **underinvestment**, and defining what it should be is critical to **health and disease management**

is weak and always under pressure

How to address this problem


- I want to begin with looking at why we respond to disease problems
- How decisions are made on the interventions selected
- Ability of societies to manage the control of disease
- Suggestions on how this could be improved through a resource allocation lens

Disease impact and response

RVC



LCIRAH



Health Impact

Losses

Visible Losses

Dead animals
Thin animals
Animals poorly developed
Low returns
Poor quality products

Impact caused by the disease

Invisible Losses

Fertility problems
Change in herd structure
Delay in the sale of animals and products
Public health costs
High prices for livestock and livestock products

Expenditure & Reaction

Additional Costs


Medicines
Vaccines
Insecticide
Time
Treatment of products

Lost Revenue

Access to better markets denied
Sub-optimal use of technology

Impact caused by human reaction

Disease Loss – Expenditure Frontier (adapted from McInerney, 1996)



The health system

- *Where are the weaknesses?*


RVC



LCIRAH

Health systems

- › A health system is the organisation of people, institutions and resources that deliver healthcare services to meet the needs of target populations



US\$ 6.5 trillion
in 2011 (WHO, 2015)
with approximately 9.7
million medical doctors

Animal health medicines market is a
fortieth of the human medicines
market (AHI, 2015)


We estimate that there are
approximately a million vets

Human and animals (LSUs)




Per person this is equivalent to:

- **0.38 livestock units per person**
- **190 kilos of live animals per person!**
- **3 chickens, a third of a shoat, a fifth of a cow, a seventh of a pig and a tenth of a cat or dog**



Global livestock units per person by species

- (FAOSTAT, 2015; authors' analysis)



Diapositive 15


1

Add lines on the biomass of humans and animals

Jonathan Rushton, 3/15/2015

And the consequences?

- global meat consumption per person 1950 to 2011



Health system

– *the weakness*

- There is strong evidence that many of the human diseases have origins from animals (Cleaveland et al, 2001; Woolhouse & Gowtage-Sequeria, 2005)
- And that this trend has increased in the recent past (Jones et al, 2008)
- Yet our investment across the health system does not seem to reflect either the relationship between the biomass of humans to animals or the risks posed by these biomasses


How could we respond?
- Shifts in technology

RVC



LCIRAH

Change in technology



Change in technology

▸ Types of technology change

- Immune status
 - Vaccine discovery and vaccine improvements
 - Adjuvant discovery
 - Genetic resistance
- Treatments
 - Antimicrobials
- Methods of detection and delivery
 - Diagnostics
 - Logistics
 - Epidemiology


And the investments for these technology shifts

- Foundations are laid with the education of people
- There also needs to be research into the specific topics
- And research requires people and institutions to be developed
 - These are fixed cost investments of core activities

Technology shift in health systems

- The classic way of thinking about technology shifts is through the lens of technological advance
- There is a tendency to forget that many of our advances have come about through managerial and institutional development change
- And this requires **fixed cost** investments in health systems across the species
- Investments that need **public funding** support alongside **private sector engagement**

Cost-benefit model for livestock disease control with fixed costs (adapted from Tisdell, 2009)



What is needed to assess the investment in fixed cost for the animal health system

- A report on these costs (Civic Consulting for OIE, 2009) indicated that the following issues had an influence on spending
 - Land area, population and livestock
 - Economic development
 - Trade
 - Local ecology and animal health situation
 - Existence of a private veterinary sector
- It did not come up with estimates of what the investments should be to get the best animal health status


And evidence from specific diseases

RVC



LCIRAH

FMD cases in UK 1922 to 1966



Issues around the health

- v Imagine a world without the investments of people who surrounded Jenner and Pasteur
- v Imagine a world without the investments over time on smallpox, rinderpest, foot-and-mouth disease
- v These have been, in human history terms, long term investments leading to significant perpetual gains in health and welfare
 - In the case of animal disease through income, food supply and maintenance of wealth

Summary


RVC




LCIRAH

The gap

- ▶ OIE are working hard to collect and update data on the animal health system – through ongoing databases and the PVS
- ▶ **There is simply a lack of data** in identifying what is the optimal investment in the health system due to the difficulties in
 - What the balance should be between species
 - What is the impact of diseases not just in humans but across species





Key messages

- Need for **evidence** which requires data collection and analysis of:
 - Species and their production systems
 - Losses in production and our reaction to the presence of disease
 - Weaknesses in technologies and their prices
 - The weaknesses in the overall health system
- Presenting **business cases** that use economics for **strategic investments**
- Addressing problems with **best scientific practice** with **monitoring** and **advocacy** on how they work

Further information

- ▼ For more information on NEAT please look at
 - www.neat-network.eu
- ▼ For information on the work we are involved in with agriculture and health please look at
 - <http://www.lcirah.ac.uk/home>
- ▼ For courses offered at RVC please look at
 - <http://www.rvc.ac.uk/Postgraduate/Distance/Index.cfm>
 - <http://www.atp-ilhp.org>



References

- › Animal Health Institute (2015) About Animal Medicines. Accessed at <http://www.ahi.org/about-animal-medicines/industry-statistics/> June 2015
- › Civic Consulting (2009) Cost of National Prevention Systems for Animal Diseases and Zoonoses in Developing and Transition Countries. Report for OIE, Paris, France. 381 pages
- › Cleavland, S.; Laurenson, M.K.; Taylor, L.H. (2001) Diseases of humans and their domestic mammals: pathogen characteristics, host range and the risk of emergence Philos Trans R Soc Lond B Biol Sci. 2001 Jul 29;356(1411):991-9.
- › Henry J. Kaiser Family Foundation (2015) Global Health Facts. Accessed <http://kff.org/global-indicator/physicians/> June 2015
- › Jones, Patel N.G.; Levy M.A.; Storeygard A.; Balk D.; Gittleman J.L.; Daszak P. (2008) Global trends in emerging infectious diseases. *Nature* **451**, 990-993
- › McInerney J. (1996) Old economics for new problems – Livestock disease: Presidential address. *Journal of Agricultural Economics* 47 (3) pp 295-314
- › McInerney, J. P. Howe, K. S. Schepers, J.A. (1992) A framework for the economic analysis of disease in farm livestock. *Preventive Veterinary Medicine.*13: 2, 137-154.
- › Rushton, J. (2009) *The Economics of Animal Health and Production.* CABI, UK 364 pages
- › WHO (2015) Spending on health care a global overview. Accessed at <http://www.who.int/mediacentre/factsheets/fs319/en/> June 2015
- › Woolhouse, M.E.J.; Gowtage-Sequeria, S. (2005) Host Range and Emerging and Reemerging Pathogens. *Emerging Infectious Diseases* Vol. 11, No. 12